Table 1.
Patient characteristics.
| n (%) | ||
|---|---|---|
| Sex | Male | 13 (36.1) |
| Female | 23 (63.9) | |
| Age | Median (range) | 80 (75–92) |
| ≥80 years | 52.8 % | |
| >85 years | 11.1 % | |
| PS |
0 1 |
8 (22.2) 28 (77.8) |
| Histology | Adenocarcinoma | 35 (97.2) |
| Adenocarcinoma + SCLC | 1 (2.8) | |
| Stage | IIIB | 1 (2.8) |
| IV | 25 (69.4) | |
| Relapse after surgery | 10 (27.8) | |
| EGFR mutation | T790M | 36 (100.0) |
| Exon 19 deletion | 22 (61.1) | |
| L858R | 11 (30.6) | |
| G719X | 1 (2.8) | |
| Smoking status | Ex-smoker | 11(30.6) |
| Pre-treatment | Surgery | 12 (33.3) |
| Chemotherapy EGFR-TKI Afatinib Erlotinib Gefitinib |
13 (36.1) 36 (100.0) 5 (13.9) 10 (27.8) 21 (58.3) |
|
| Radiotherapy | 10 (27.8) | |
| Thoracic drainage | 4 (11.1) | |
| Metastasis site | Lung | 18 (50.0) |
| Pleural dissemination | 12 (33.3) | |
| Brain | 15 (41.7) | |
| Bone | 12 (33.3) | |
| Liver | 8 (22.2) |
PS: performance status, SCLC: small cell lung cancer.